Similarly, in the AMI subgroup analysis of the primary CHD + T2DM cohort, the effect of short-term SGLT2 inhibitor use did not reach statistical significance (P > 0.05; Supplementary Table S22), which is likely attributable to the substantially reduced sample size in this particular subgroup analysis that critically constrained the statistical power. Here, SLC5A2 is linked to coronary artery disorder.